MDMA
Open this page in the complete interactive Atlas
Read the findings from PTSD and other psychiatric studies alongside the schizophrenia tolerability study and reports of catatonia after ecstasy exposure.
How might it help?
MDMA increases signaling through serotonin, norepinephrine and dopamine. Changes in emotional processing have motivated studies pairing it with psychotherapy for PTSD. The UCLA schizophrenia study asks whether people with stable illness tolerate exposure before drawing conclusions about possible social benefits. NIDA review of MDMA pharmacology Original source UCLA study Original source
24 records
MDMA · Catatonia after recreational ecstasy exposureA 1993 report described low blood sodium and catatonic stupor after ecstasy.
Study or clinical setting
Case reports and correspondence
What was reported
A 1993 report described low blood sodium and catatonic stupor after ecstasy. Later authors reported adolescent catatonia after recreational exposure and an adult with chronic MDMA use, psychosis and catatonic signs who improved after electroconvulsive therapy (ECT).
What limits the finding
These reports concern illness after exposure. No human treatment trial of MDMA for catatonia was identified in this search. Tablet composition, other psychiatric illness and medical complications limit causal attribution.
Sources
- The original BMJ case report describes stupor alongside a potentially serious metabolic disturbance. Hyponatraemia and catatonic stupor after taking ecstasy Original source
- A subsequent letter discusses the 1993 report and should not be counted as an independent treatment or replication. Catatonic stupor after ecstasy — correspondence Original source
- Clinicians describe a 16-year-old with a history of recreational ecstasy use who presented with mutism and immobility. Catatonia in an adolescent after ecstasy use Original source
- The authors discuss diagnostic uncertainty, including possible underlying bipolar illness, during the clinical course. Electroconvulsive therapy in MDMA-associated psychosis and catatonic features Original source
- This search lets readers recheck for newly registered studies in which MDMA is listed as an intervention for catatonia. ClinicalTrials.gov search for catatonia and MDMA Original source
MDMA · Schizophrenia · tolerability and social motivationUCLA plans to study 20 adults with clinically stable schizophrenia.
Study or clinical setting
Early open-label tolerability study
What was reported
UCLA plans to study 20 adults with clinically stable schizophrenia. Investigators monitor disorganized speech, delusions and hallucinations and explore whether MDMA changes social motivation. This is an early test of whether further study is feasible.
What limits the finding
The registry lists recruiting and has no posted outcomes. There is no demonstrated benefit for schizophrenia symptoms, acute psychosis or catatonia from this trial.
Study identifiers · NCT05770375
Sources
- The study team explains the rationale for studying social motivation in a selected group of people with stable illness. UCLA study description Original source
- The protocol specifies safety thresholds for worsening positive symptoms, the enrollment target and eligibility criteria. Tolerability of MDMA in Schizophrenia Original source
MDMA · Psychosis after recreational ecstasy exposureClinicians describe persistent hallucinations, paranoia or disorganization beginning after reported recreational ecstasy use.
Study or clinical setting
Individual case reports
What was reported
Clinicians describe persistent hallucinations, paranoia or disorganization beginning after reported recreational ecstasy use. In these reports MDMA exposure preceded symptoms and people subsequently needed psychiatric care.
What limits the finding
Individual histories cannot establish the frequency of this outcome or distinguish drug effects, unverified tablet contents and an underlying psychotic disorder.
Sources
- A case report describes psychiatric and medical illness after an alleged single ingestion of an ecstasy tablet. Persistent psychosis and medical complications after ecstasy Original source
- A separate patient report documents a prolonged course after reported recreational exposure. Persistent psychosis following a single ingestion of ecstasy Original source
MDMA · Post-traumatic stress disorder (PTSD)MAPP1 enrolled 90 adults with severe PTSD.
Study or clinical setting
Two phase 3 randomized, double-blind, placebo-controlled trials
What was reported
MAPP1 enrolled 90 adults with severe PTSD. MAPP2 enrolled 104 with moderate or severe PTSD. In both, the group assigned MDMA plus therapy had larger reductions in clinician-rated PTSD symptoms than the group assigned placebo plus the same therapy. In MAPP2 the estimated mean decrease on the CAPS-5 scale was 23.7 versus 14.8 points.
What limits the finding
Participants could often infer their assignment. The US FDA declined the 2024 application over interpretation and safety data. MAPS acknowledged a reported resubmission in August 2026. No subsequent US approval was identified in the review. Australia has a restricted authorized-psychiatrist access pathway for PTSD. Neither decision establishes efficacy for catatonia or schizophrenia.
Study identifiers · NCT03537014 · NCT04077437
Sources
- This trial reports short-term changes in PTSD symptom severity and functional impairment in severe PTSD. MAPP1 phase 3 results Original source
- The publication gives symptom and functional outcomes, adverse events and masking assessments in the second pivotal trial. MAPP2 confirmatory trial Original source
- The regulator explained why the submitted evidence was insufficient for US approval, including difficulties with masking and adverse-event assessment. FDA complete response letter Original source
- The research nonprofit responded to external reporting of a new submission. This statement does not document an FDA approval. MAPS statement on the reported 2026 resubmission Original source
- The regulator describes access to unapproved MDMA for PTSD through specifically authorized psychiatrists. Australian Therapeutic Goods Administration access guidance Original source
- The first pivotal registry record describes the severe-PTSD population and the prespecified clinician-rated primary endpoint. A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) Original source
- The second pivotal registry record describes the confirmatory study and its moderate-to-severe PTSD population. A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) Original source
MDMA · PTSD and relationship functioningA pilot integrated MDMA with conjoint therapy in six couples in which one partner had PTSD.
Study or clinical setting
Uncontrolled couple-therapy pilot
What was reported
A pilot integrated MDMA with conjoint therapy in six couples in which one partner had PTSD. A separate 2026 study in eight veterans and their partners also observed improvements in PTSD and relationship scores, with some loss of relationship gains at follow-up.
What limits the finding
Both studies were small and lacked control groups. Changes could reflect conjoint psychotherapy, partner support, expectancy or other factors.
Study identifiers · NCT02876172 · NCT06044675
Sources
- The authors describe the couples treated and report both partner- and patient-reported outcomes. MDMA-facilitated cognitive-behavioral conjoint therapy for PTSD Original source
- Eight veteran–partner pairs participated in a separate open-label study that reported relationship, PTSD and safety outcomes. Pilot in veterans with PTSD and their partners Original source
- The registry describes the original conjoint-therapy feasibility pilot. MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD Original source
- This separate trial studies how adding MDMA to conjoint PTSD therapy affects clinical and relationship outcomes. MDMA-Assisted CBCT for PTSD vs CBCT RCT Original source
MDMA · Major depressive disorderTwelve adults with major depressive disorder took part in a feasibility study.
Study or clinical setting
Open-label proof-of-principle study with follow-up
What was reported
Twelve adults with major depressive disorder took part in a feasibility study. Depression scores fell after treatment. A later publication followed the same participants to seven months.
What limits the finding
There was no placebo or psychotherapy-only comparison. The follow-up concerns the original cohort, so independent controlled studies are needed to estimate benefit and durability.
Study identifiers · EudraCT 2021-000805-26
Sources
- The original Norwegian pilot reports feasibility, adverse events and depression scores during short-term follow-up. MDMA-assisted therapy for major depressive disorder Original source
- The investigators reassessed the original participants to examine the longer-term course of depressive symptoms. Seven-month follow-up in major depressive disorder Original source
- The European record identifies the Norwegian feasibility protocol and its prospectively specified objectives. European trial registration Original source
MDMA · Social anxiety in autistic adultsTwelve autistic adults with substantial social anxiety entered the study.
Study or clinical setting
Randomized, blinded, placebo-controlled pilot
What was reported
Twelve autistic adults with substantial social anxiety entered the study. Eight were assigned MDMA-assisted psychotherapy and four received placebo with psychotherapy. Social-anxiety ratings improved more in the active group, with the difference still evident at six months.
What limits the finding
Four people formed the comparison group. The outcome was social anxiety in a selected group of adults, with no conclusions about catatonia or the broader autistic population.
Study identifiers · NCT02008396
Sources
- The full report gives Liebowitz Social Anxiety Scale outcomes, follow-up data and the individual trajectories of this small group. Randomized pilot in autistic adults Original source
- The protocol describes the social-anxiety eligibility requirements and the psychotherapy and placebo comparison. Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults Original source
MDMA · Social anxiety disorderA trial of 20 adults with social anxiety disorder reported a larger 16-week improvement on the Liebowitz Social Anxiety Scale in participants assigned to immediate MDMA-assisted therapy than in those assigned to wait.
Study or clinical setting
Small randomized, open-label, wait-list-controlled trial
What was reported
A trial of 20 adults with social anxiety disorder reported a larger 16-week improvement on the Liebowitz Social Anxiety Scale in participants assigned to immediate MDMA-assisted therapy than in those assigned to wait.
What limits the finding
The wait-list group did not receive a matching placebo and psychotherapy package during the initial comparison. Expectation, attention and psychotherapy can influence the observed difference.
Study identifiers · NCT05138068
Sources
- The 2026 report describes clinical outcomes, functional measures and tolerability in the broader social-anxiety population. Randomized wait-list trial in social anxiety disorder Original source
- The registered trial uses immediate and delayed treatment groups to compare changes in social anxiety. Social Anxiety MDMA-Assisted Therapy Investigation Original source
MDMA · Anxiety associated with a life-threatening illnessEighteen patients with anxiety related to a life-threatening illness were randomized.
Study or clinical setting
Small randomized, blinded, placebo-controlled pilot
What was reported
Eighteen patients with anxiety related to a life-threatening illness were randomized. Mean trait-anxiety scores fell by 23.5 points in the MDMA group and 8.8 with placebo. The prespecified between-group comparison missed conventional statistical significance (p = 0.056).
What limits the finding
The estimate is imprecise. A larger trial would be necessary to establish whether the intervention improves this form of anxiety.
Study identifiers · NCT02427568
Sources
- The authors give group changes in trait anxiety, the primary statistical comparison and secondary outcomes. Pilot trial of anxiety related to life-threatening illness Original source
- The registry identifies the primary anxiety endpoint and the timing of the blinded comparison. MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness Original source
MDMA · Alcohol use disorderFourteen adults received MDMA-assisted psychotherapy after clinical detoxification.
Study or clinical setting
Open-label feasibility study after alcohol detoxification
What was reported
Fourteen adults received MDMA-assisted psychotherapy after clinical detoxification. Participants reported substantially lower average alcohol consumption nine months later than before detoxification.
What limits the finding
The comparison was with participants’ own pre-detox drinking. The contributions of detoxification, therapy, time and MDMA cannot be separated.
Study identifiers · NCT04158778
Sources
- The publication describes recruitment, tolerability, drinking outcomes and the limits of this first feasibility cohort. Bristol–Imperial MDMA in Alcoholism study Original source
- The registry describes the open-label alcohol dependence study and follow-up after community detoxification. Bristol Imperial MDMA in Alcoholism Study Original source
MDMA · Co-occurring PTSD and alcohol use disorderA 2026 pilot followed ten veterans with both diagnoses.
Study or clinical setting
Open-label veteran pilot and subsequent randomized protocols
What was reported
A 2026 pilot followed ten veterans with both diagnoses. PTSD severity fell and participants reported fewer heavy-drinking days. The authors judged the change in alcohol outcomes below their threshold for clinical significance. Separate controlled trials address both disorders.
What limits the finding
The pilot was too small and uncontrolled to establish an effect on drinking or to determine how much change came from psychotherapy. Larger trials have separate protocols and outcomes.
Study identifiers · NCT05943665 · NCT07118839 · NCT05709353
Sources
- The authors report completion, PTSD severity and several drinking measures after the open-label intervention. Pilot outcomes in veterans with PTSD and alcohol use disorder Original source
- The Australian protocol describes a controlled test of MDMA-assisted prolonged exposure for co-occurring PTSD and alcohol use disorder. MPATHY Australian trial protocol Original source
- The Veterans Affairs study plans to compare MDMA-assisted therapy with the same psychotherapy and an active comparator. VA announcement of its randomized PTSD and alcohol use disorder trial Original source
- The Providence study record specifies alcohol consumption outcomes alongside PTSD measures. MDMA for AUD/PTSD Comorbidity Original source
- This separate VA trial targets 80 veterans and uses randomized assignment to test the combined treatment. MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder Original source
- The Sydney protocol combines prolonged exposure therapy with the study intervention for participants with both diagnoses. MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder Original source
MDMA · Postpartum PTSD with opioid use disorderThe University of New Mexico plans to study postpartum participants with both PTSD and opioid use disorder.
Study or clinical setting
Registered open-label pilot
What was reported
The University of New Mexico plans to study postpartum participants with both PTSD and opioid use disorder. The primary outcome concerns PTSD symptoms.
What limits the finding
No study results were posted in the reviewed record. The design cannot establish an effect on opioid use disorder, broader perinatal safety or outcomes during pregnancy.
Study identifiers · NCT05219175
Sources
- The study record identifies the postpartum population, an estimated enrollment of 15 and the PTSD endpoint. MDMA for Co-occurring PTSD and OUD After Childbirth Original source
MDMA · Obsessive-compulsive disorderA Stanford study asks whether MDMA-assisted cognitive behavioral therapy improves obsessive-compulsive symptoms, measured using the Yale-Brown Obsessive Compulsive Scale.
Study or clinical setting
Randomized phase 2 psychotherapy augmentation study
What was reported
A Stanford study asks whether MDMA-assisted cognitive behavioral therapy improves obsessive-compulsive symptoms, measured using the Yale-Brown Obsessive Compulsive Scale. The active comparison uses methamphetamine with CBT.
What limits the finding
The target enrollment is 40. The reviewed registry record lists recruiting and has no posted results.
Study identifiers · NCT05783817
Sources
- Stanford describes participant eligibility, the comparison groups and the study’s focus on OCD symptoms. Stanford study description Original source
- The prespecified comparison and clinician-rated OCD endpoint are available in the trial record. MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) Original source
MDMA · Borderline personality disorderYale is examining short-term changes in self-reported social cognition in adults with borderline personality disorder after study-administered MDMA.
Study or clinical setting
Early open-label social-cognition study
What was reported
Yale is examining short-term changes in self-reported social cognition in adults with borderline personality disorder after study-administered MDMA.
What limits the finding
The registry targets ten adults and has no posted results. The primary endpoint does not establish a durable effect on symptoms, relationships or functioning.
Study identifiers · NCT06683014
Sources
- The protocol specifies social cognition as its primary measure and describes the small single-group design. MDMA in Borderline Personality Disorder Original source
MDMA · Pathological narcissismA University of Washington trial studies MDMA-assisted therapy in participants with pathological narcissism.
Study or clinical setting
Open-label single-group feasibility study
What was reported
A University of Washington trial studies MDMA-assisted therapy in participants with pathological narcissism. The main measures include participants’ ratings on the Pathological Narcissism Inventory.
What limits the finding
Twelve people were enrolled. The reviewed record has no posted results, and a single group cannot separate treatment effects from expectation or time.
Study identifiers · NCT06565494
Sources
- The study lists actual enrollment, outcome instruments and follow-up for the therapy cohort. MDMA-Assisted Therapy for Pathological Narcissism Original source
MDMA · Adjustment disorder in people with cancer and their partnersThe study plans to enroll ten patient–partner pairs affected by cancer.
Study or clinical setting
Registered open-label dyadic pilot
What was reported
The study plans to enroll ten patient–partner pairs affected by cancer. It measures adjustment-disorder symptoms and relationship functioning after MDMA-assisted therapy.
What limits the finding
The registry has no posted results. Any eventual estimate requires attention to the small sample and the paired design.
Study identifiers · NCT05584826
Sources
- The study record describes the cancer population, participation by a concerned significant other and the relationship and symptom outcomes. MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other Original source
MDMA · Eating-disorder symptoms in people with severe PTSDInvestigators examined changes in Eating Attitudes Test scores among people enrolled for severe PTSD.
Study or clinical setting
Exploratory analysis of a phase 3 PTSD trial
What was reported
Investigators examined changes in Eating Attitudes Test scores among people enrolled for severe PTSD. They reported exploratory differences favoring MDMA-assisted therapy on measures of eating-related symptoms.
What limits the finding
Selection was based on PTSD. Outcomes on a symptom questionnaire cannot establish efficacy for diagnosed anorexia nervosa, binge-eating disorder or bulimia nervosa.
Study identifiers · NCT03537014
Sources
- This secondary publication examines eating attitudes in the same PTSD sample enrolled in the MAPP1 trial. Exploratory eating-symptom analysis from MAPP1 Original source
- This is the original PTSD trial underlying the exploratory analysis, not an independent eating-disorder cohort. A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) Original source
MDMA · Anorexia nervosa and binge-eating disorderA proposed multi-site study would have examined MDMA-assisted psychotherapy for restricting-type anorexia nervosa and binge-eating disorder.
Study or clinical setting
Registered trial withdrawn before enrollment
What was reported
A proposed multi-site study would have examined MDMA-assisted psychotherapy for restricting-type anorexia nervosa and binge-eating disorder.
What limits the finding
The registry lists zero participants enrolled. This protocol produced no patient outcomes.
Study identifiers · NCT04454684
Sources
- The registration identifies the two proposed indications and documents withdrawal before any participant enrolled. A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders Original source
MDMA · Bulimia nervosaA Mount Sinai study compares two versions of MDMA-assisted therapy with standard care in bulimia nervosa.
Study or clinical setting
Registered comparative pilot
What was reported
A Mount Sinai study compares two versions of MDMA-assisted therapy with standard care in bulimia nervosa. The main measure is the frequency of binge-eating episodes.
What limits the finding
The reviewed record lists recruiting, with a target of 40 and no posted results. The treatment’s effect on bingeing or compensatory behaviors remains unknown.
Study identifiers · NCT07542145
Sources
- The protocol describes the three groups, adaptations for bulimia and the prespecified binge-eating endpoint. MDMA Assisted Therapy for BN Original source
MDMA · Social functioning in autistic adults · R-MDMAFive autistic adults participated in a study of R-MDMA, one of the two mirror-image forms of MDMA.
Study or clinical setting
Open-label pilot of the R-enantiomer DT402
What was reported
Five autistic adults participated in a study of R-MDMA, one of the two mirror-image forms of MDMA. The sponsor described exploratory changes in rigidity and social engagement.
What limits the finding
The report is sponsor-disclosed and uncontrolled. The preparation differs from the mixed-enantiomer MDMA in the social anxiety trial. Its findings cannot establish a change in core autism features.
Study identifiers · NCT07303907
Sources
- The sponsor describes its interpretation of outcomes in a securities filing, rather than a peer-reviewed controlled comparison. Sponsor disclosure of exploratory findings Original source
- The registry confirms the five-person single-group design, completed status and R-MDMA formulation. A Phase 2A Trial of DT402 for Autism Spectrum Disorder Original source
MDMA · PTSD with moral injuryA study in veterans with PTSD and moral injury assesses PTSD symptoms and explores changes in relationships, hyperarousal and neural responses.
Study or clinical setting
Registered trial in veterans
What was reported
A study in veterans with PTSD and moral injury assesses PTSD symptoms and explores changes in relationships, hyperarousal and neural responses.
What limits the finding
No outcomes were posted in the reviewed record. Moral injury here describes a study population and mechanism under investigation.
Study identifiers · NCT06394284
Sources
- The registration describes a target of 60 and lists symptom and mechanistic measures. Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury Original source
MDMA · Occupational distress in healthcare providers and first respondersOne protocol includes healthcare workers and first responders with adjustment disorder or PTSD.
Study or clinical setting
Registered studies of stress symptoms and well-being
What was reported
One protocol includes healthcare workers and first responders with adjustment disorder or PTSD. Another focuses on well-being among mental healthcare providers.
What limits the finding
The populations and outcomes differ. These records have no posted efficacy results and cannot establish effectiveness for occupational burnout.
Study identifiers · NCT05455996 · NCT07102576
Sources
- This protocol follows healthcare workers and first responders with stress disorders and tracks trauma-related symptoms. MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders Original source
- This separate protocol measures well-being in mental healthcare providers using the Mental Health Continuum scale. MDMA-Assisted Therapy for Mental Healthcare Providers Original source
MDMA · Dissociation, depression and sleep symptoms in PTSDA 2026 review combined seven randomized trials of MDMA-assisted psychotherapy for PTSD.
Study or clinical setting
Systematic review of randomized PTSD trials
What was reported
A 2026 review combined seven randomized trials of MDMA-assisted psychotherapy for PTSD. The pooled data suggested improvements in dissociative symptoms, depressive symptoms and functional disability. The analysis found no clear improvement in sleep quality relative to controls.
What limits the finding
These outcomes came from PTSD populations and cannot establish benefit for a primary dissociative or sleep disorder. The studies shared a sponsor, and participants could often identify their assignment.
Sources
- The review separates each outcome and describes limitations from masking, small studies and differences in psychotherapy. Systematic review of symptoms and functioning in PTSD Original source
MDMA · Chronic pain in people with PTSDAmong 32 participants who completed pain assessments during a PTSD study, people starting with moderate or high pain reported less intense pain after therapy.
Study or clinical setting
Exploratory analysis of open-label PTSD data
What was reported
Among 32 participants who completed pain assessments during a PTSD study, people starting with moderate or high pain reported less intense pain after therapy. Nine participants in the highest-pain subgroup also reported less pain-related disability.
What limits the finding
The subgroups were small and there was no control arm. The analysis cannot establish analgesic efficacy. Separate protocols investigate fibromyalgia and chronic neuropathic pain.
Study identifiers · NCT03282123 · NCT06066853 · NCT07301632
Sources
- The researchers analyzed a secondary pain measure and reported the change separately by initial pain severity. Pain and disability in an open-label PTSD trial Original source
- The registry describes the parent open-label PTSD study that supplied the exploratory pain data. Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD Original source
- This separate study measures pain severity and interference in people with fibromyalgia. MDMA-assisted Therapy for Fibromyalgia Original source
- This separate feasibility study enrolls people with severe chronic neuropathic pain. Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial Original source